EuroNanoMed III | February 2018 | 11
NEWSLETTER 7 EuroNanoMed III
Coordinator: Tobias Knopp, University Medical Center Hamburg
Eppendorf, Germany [email protected]
Partners: Peter Ludewig, University Medical Center
Hamburg-Eppendorf, Germany Jan Niehaus, CAN GmbH, Germany Mauro
Magnani, University of Urbino, Italy Emine Ulku Saritas, Bilkent
University, Turkey Yan Yan, University College Dublin, Ireland
Despite 20 years of experience with thrombolysis of cerebral
blood clots with tissue-type plasminogen activator (rt-PA), fifty
percent of patients remain disabled for life. A narrow therapeutic
time window, insufficient thrombolysis rates, serious side effects,
and time-consuming imaging techniques decrease the efficacy of
stroke treatment. MAGneTISe aims to develop a new, two-pronged
approach by combining the therapy and monitoring of stroke patients
with Magnetic Particle Imaging (MPI).This new imaging technique
enables rapid assessment of cerebral perfusion (real-time-MPI), as
well as the steering of superparamagnetic iron oxide nanoparticles
(SPIO) by magnetic fields (force-MPI). We will develop strategies
for continuous bedside cerebral perfusion monitoring, using red
blood cells (RBC) as a biomimetic tracer-delivery system for the
SPIOs, which otherwise would have been quickly eliminated. This
method will enable rapid diagnosis of stroke or bleeding and
facilitate faster treatment and better patient outcomes. Using the
magnetic fields of the MPI system, we will trap the coupled
nanoparticles in the occluded vessel, which will locally increase
the amount of active enzyme, resulting in an increased rate of
successful revascularization while decreasing systemic side
effects.
MAGneTISeMAGNETIC PARTICLE IMAGING FOR THE TREATMENT AND IMAGING
OF STROKE
MAGneTISe aims to״develop a new, two-pronged approach by
combining the therapy and monitoring of stroke patients with
Magnetic Particle Imaging.״
